**WHAT IS CLAIMED IS:**

1. The use of a pharmaceutical composition comprising an active ingredient comprising one or more analgesic agents selected from the group consisting of aspirin, ~~ibuprofen,~~ naproxen, naproxen sodium, ~~indomethacin,~~ nabumetone and acetaminophen, in the manufacture of a medicament for the treatment of bedwetting.

2. The use of the pharmaceutical composition of Claim 1, wherein said pharmaceutical composition is formulated for immediate release.

3. The use of the pharmaceutical composition of Claim 1, wherein said pharmaceutical composition is formulated for extended-release.

4. The use of the pharmaceutical composition of Claim 2 or 3, wherein said pharmaceutical composition is further coated with an enteric coating.

5. The use of the pharmaceutical composition of Claim 1, wherein said pharmaceutical composition is formulated for delayed-release.

6. The use of the pharmaceutical composition of any one of Claims 1-5, wherein said pharmaceutical composition comprises one or more analgesic agents in an amount of 10-1000 mg per analgesic agent.

7. The use of the pharmaceutical composition of any one of Claims 1-6, wherein said one or more analgesic agents comprises acetaminophen.

8. The use of the pharmaceutical composition of Claim 7, wherein said pharmaceutical composition comprises acetaminophen in an amount of 10-300 mg.

9. The use of the pharmaceutical composition of Claim 7, wherein said pharmaceutical composition comprises acetaminophen in an amount of 300-1000 mg.

10. The use of the pharmaceutical composition of any one of Claims 1-9, wherein said one or more analgesic agents consist of acetaminophen and one other analgesic agent selected from the group consisting of aspirin, ~~ibuprofen,~~ naproxen, naproxen sodium, ~~indomethacin,~~ and nabumetone.

11. The use of the pharmaceutical composition of any one of Claims 1-10, wherein said active ingredient further comprises an antimuscarinic agent.

12. The use of the pharmaceutical composition of any one of Claims 1-11, wherein said active ingredient further comprises an antidiuretic.

13. The use of the pharmaceutical composition of any one of Claims 1-12, wherein said active ingredient further comprises a spasmolytic.

14. The use of the pharmaceutical composition of any one of Claims 1-13, wherein said active ingredient further comprises an inhibitor of phosphodiesterase type 5 (PDE 5 inhibitor).

15. The use of a pharmaceutical composition comprising an active ingredient comprising one or more analgesic agents in an amount of 1-1000 mg per agent in the manufacture of a medicament for the treatment of bedwetting, wherein said one or more analgesic agents are selected from the group consisting of aspirin, ~~ibuprofen,~~ naproxen, naproxen sodium, ~~indomethacin,~~ nabumetone, and acetaminophen and wherein said pharmaceutical composition is formulated for immediate release, extended release, delayed release or combinations thereof, wherein said active ingredient further comprises an inhibitor of phosphodiesterase type 5 (PDE 5 inhibitor).

16. The use of the pharmaceutical composition of Claim 15, wherein said one or more analgesic agents comprises acetaminophen.

17. The use of the pharmaceutical composition of Claim 16, wherein said one or more analgesic agents further comprises an analgesic agent selected from the group consisting of aspirin, ~~ibuprofen,~~ naproxen, naproxen sodium, ~~indomethacin~~ and nabumetone.

18. The use of the pharmaceutical composition of Claim 15-17, wherein said active ingredient further comprises an agent selected from the group consisting of antimuscarinic agents, antidiuretics, spasmolytics and PDE 5 inhibitors.

19. Pharmaceutical composition comprising:
one or more analgesic agents;
desmopressin; and
a pharmaceutically acceptable carrier,
wherein said pharmaceutical composition is formulated for immediate release, extended release, delayed release or combinations thereof, for use in the treatment of bedwetting.

20. The pharmaceutical composition of Claim 19, wherein said one or more analgesic agents comprises acetaminophen.

21. The use of the pharmaceutical composition of Claim 1, wherein said pharmaceutical composition is in a liquid or solid formulation.

22. The pharmaceutical composition of Claim 19, wherein said pharmaceutical composition is in a liquid or solid formulation.

23. The use of a pharmaceutical composition comprising an active ingredient comprising one or more analgesic agents selected from the group consisting of aspirin, naproxen, naproxen sodium, nabumetone and acetaminophen, in the manufacture of a medicament for the treatment

of bedwetting, wherein said active ingredient further comprises an inhibitor of phosphodiesterase type 5 (PDE 5 inhibitor).